Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) EBITDA (2023 - 2026)

Kura Oncology has reported EBITDA over the past 4 years, most recently at -$74.7 million for Q1 2026.

  • Quarterly EBITDA fell 30.62% to -$74.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$295.9 million through Mar 2026, down 64.31% year-over-year, with the annual reading at -$278.4 million for FY2025, 61.91% down from the prior year.
  • EBITDA was -$74.7 million for Q1 2026 at Kura Oncology, up from -$80.9 million in the prior quarter.
  • Over five years, EBITDA peaked at -$19.6 million in Q4 2024 and troughed at -$80.9 million in Q4 2025.
  • The 4-year median for EBITDA is -$50.5 million (2024), against an average of -$51.6 million.
  • Year-over-year, EBITDA soared 51.71% in 2024 and then tumbled 313.37% in 2025.
  • A 4-year view of EBITDA shows it stood at -$40.5 million in 2023, then soared by 51.71% to -$19.6 million in 2024, then tumbled by 313.37% to -$80.9 million in 2025, then increased by 7.61% to -$74.7 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's EBITDA are -$74.7 million (Q1 2026), -$80.9 million (Q4 2025), and -$73.9 million (Q3 2025).